Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Dapagliflozin Propanediol for the Treatment of Localized Prostate Cancer

Trial Status: closed to accrual and intervention

This phase I trial determines the side effects of dapagliflozin propanediol in treating patients with prostate cancer that has not spread to other places in the body (localized). Dapagliflozin propanediol is a drug used to reduce the risk of heart failure and to improve glycemic control in patients with type 2 diabetes. This trial aims to see whether dapagliflozin propanediol may help treat prostate cancer because it can change glucose metabolism in the body and decrease the availability of glucose to the tumor (which is something tumors need to grow).